Actionable news
0
All posts from Actionable news
Actionable news in ADMA: ADMA BIOLOGICS Inc,

ADMA Biologics Announces Pricing of Public Offering of Common Stock

RAMSEY, N.J., Apr 28, 2016 (GLOBE NEWSWIRE via COMTEX) --

ADMA Biologics, Inc. ADMA, -1.96% a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public offering price of $6.50 per share, resulting in gross proceeds of approximately $12.3 million. Members of management and the Board of Directors participated in excess of ten percent in the offering.

The offering is expected to close on May 3, 2016, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to 283,846 additional shares of common stock to cover over-allotments, if any.

Raymond James & Associates, Inc. is acting as sole book-running manager and Ladenburg Thalmann is acting as lead manager in connection with the offering. Laidlaw & Company (UK) Ltd. and Maxim Group LLC are acting as financial advisors to the company.

The securities described above are being offered by the company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-200638) previously filed with the Securities and Exchange Commission (SEC), and declared effective on December 23, 2014. A preliminary prospectus supplement and an accompanying prospectus related to the offering were filed with the SEC on April 27, 2016. A final prospectus supplement and an accompanying prospectus related to the offering will be filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus relating to the offering can be obtained on the SEC's website at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, FL 33716, or by telephone at (800) 248-8863, or by e-mail at prospectus@raymondjames.com.

Before investing in the offering, you should read in their entirety the prospectus supplement and its accompanying prospectus and the other documents that the company has filed with the SEC that are incorporated by reference in the prospectus supplement and its accompanying prospectus, which provide more information about the company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy...


More